HealioImmunotherapy plus high-dose chemotherapy effective in primary CNS lymphomaHealioThe multicenter study included 44 patients with newly diagnosed primary central nervous system lymphoma treated with methotrexate, temozolomide and rituximab inducti…
|
Lilly Scraps Oncology Candidate – Analyst Blog – NASDAQ.com
NASDAQ … the phase III PRELUDE study showed that enzastaurin failed to show a statistically significant improvement in disease-free survival compared to placebo in patients at high risk of relapse following treatment with Roche’s ( RHHBY ) Rituxan … |
Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in …PharmiWeb.com (press release)The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse …
|
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
Seeking Alpha OB) Avastin (bevacizumab), Herceptin (trastuzumab), Rituxan (rituximab), and Zelboraf (vemurafenib). This article is the first of three articles about Array. This article looks at Array’s promising collaborations with some of the biggest names in the … |
Clinical Notes: Cause of Death Often False – MedPage TodayMedPage TodayEnzastaurin is a serine-threonine kinase inhibitor that inhibits tumor angiogenesis by targeting protein kinase C-beta and the PI3K/AKT pathway. The lymphoma trial had enrolled pati…
|
ImmunoGen’s Management Presents at Credit Suisse Antibody Day Conference …
Seeking Alpha CD-37 is primarily found on NHL and also it’s generally found in the same place of CD20 as which is a supposed target for rituximab. Significant disease, one of the interesting aspects of the design of CD37 or IMGN529 is the fact that we have very … |
 Dividend.com |
Lilly Halts Drug Development After Failed Trial
Inside INdiana Business (press release) The study failed to show a statistically significant increase compared to placebo in disease-free survival in patients at high risk of relapse following rituximab-based chemotherapy. There were no new safety findings, and the safety data were … Lilly To Take $30M Charge After Relapse Cancer Drug Disappoints in TrialFox Business Enzastaurin, Eli Lilly’s Lymphoma Drug Fails In Late-Stage TrialMedical Daily Lilly Halts Development of Lymphoma Drug After Phase III FailureGenetic Engineering News |
Rituximab Works in ANCA-Linked Vasculitis – MedPage TodayMedPage TodayWASHINGTON — Rituximab given as adjunctive therapy to children with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis dramatically lowered the dosage of cyclophospham…
Intas launches Mabtas, a biosimilar version of Rituximab – PharmaBiz.compharmabiz.comIntas Pharmaceuticals Ltd. has launched Mabtas, a biosimilar version of Rituximab competent in treating diseases characterized by excessive numbers of B cells, overact…
Intas launches biosimilar version of RituximabTimes of IndiaThis biosimilar version of Rituximab, competent in treating diseases characterized by excessive numbers of B cells, overactive B cells or dysfunctional B cells like chronic lymphocytic leukemi…